Superior Determination of HPV using RNAscope™ In Situ Hybridization

Human papillomavirus (HPV) has been identified as a causal agent in oropharyngeal squamous cell carcinoma (OPSCC) with the incidence of HPV-related OPSCC increasing dramatically over the last several decades. As patients with HPV-positive OPSCC have a significantly better survival rate compared to patients with HPV-negative OPSCC, testing for HPV status is critical.

The RNAscope™ RNA in situ hybridization platform, including chromogenic detection reagents and target-specific probes for both high hisk and low risk HPV types, provides clear and unequivocal assessment of HPV status in FFPE tissue. In numerous peer-reviewed publications, the RNAscope HPV Detection Reagents have demonstrated significantly higher specificity and equivalent sensitivity in direct comparisons with p16 IHC for the presence of high-risk HPV in OPSCC.